<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765465</url>
  </required_header>
  <id_info>
    <org_study_id>S-2012-E0816-00001</org_study_id>
    <nct_id>NCT01765465</nct_id>
  </id_info>
  <brief_title>Effect of Rowachol on Prevention of Postcholecystectomy Syndrome</brief_title>
  <official_title>Effect of Rowachol on Prevention of Postcholecystectomy Syndrome After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmbio Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DongGuk University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postcholecystectomy syndrome (PCS) includes a heterogeneous group of diseases, usually
      manifested by the presence of abdominal symptoms following gallbladder removal. The
      pathogenesis of PCS has not been identified; therefore there is no consensus of medical
      treatment on PCS. The Action of Rowachol are to inhibit hepatic 3-hydroxy-3-methylglutaric
      acid(HMG)-coenzyme A(CoA) reductase, to inhibits cholesterol nucleation in bile from patients
      with cholesterol gallstones, and to promote biliary lipid secretion.

      The purpose of this study is to determine whether Rowachol is useful in the prevention of PCS
      and symptoms change after laparoscopic cholecystectomy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Number of the Participants Have Postoperative RUQ Pain</measure>
    <time_frame>postoperative 3-month</time_frame>
    <description>Right upper quadrant(RUQ) pain by European Organization for Research and Treatment of Cancer(EORTC) quality of life questionnaire(QLQ) C-30 No. 9, 19 at baseline and postoperative 3-month.
The pain score of individuals at postoperative 3-month is calculated by EORTC QLQ C-30 manual.
The pain score range is 0 to 100. Higher score means participants feel more pain(worse). If a participant's pain score is over 30, we define he/she has post operative RUQ pain. we use the number of the participants have post operative RUQ pain(score over 30) as the results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Results of Postoperative 3-month(Total Bilirubin, Direct Bilirubin)</measure>
    <time_frame>postoperative 3-month</time_frame>
    <description>laboratory test results(liver function test such as total bilirubin, direct bilirubin) measured at postoperative 3-month of Rowachol group and placebo group.
each result is mean values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Results of Postoperative 3-month(Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase)</measure>
    <time_frame>postoperative 3-month</time_frame>
    <description>laboratory test results(liver function test such as Alkaline phosphatase, Aspartate aminotransferase, Alanine aminotransferase) measured at postoperative 3-month of Rowachol group and placebo group.
each result is mean values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Results of Postoperative 3-month(WBC Count)</measure>
    <time_frame>postoperative 3-month</time_frame>
    <description>laboratory test results(WBC count) measured at postoperative 3-month of Rowachol group and placebo group.
each result is mean values.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Postcholecystectomy Syndrome</condition>
  <arm_group>
    <arm_group_label>Rowachol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rowachol</intervention_name>
    <arm_group_label>Rowachol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologic diseases scheduled for laparoscopic cholecystectomy

        Exclusion Criteria:

          -  Current immunosuppressive therapy

          -  Chemotherapy within 4 weeks before operation

          -  Radiotherapy completed longer than 4 weeks before operation

          -  Inability to follow the instructions given by the investigator

          -  Severe psychiatric or neurologic diseases

          -  Drug- and/or alcohol-abuse according to local standards

          -  Participation in another intervention-trial with interference of a primary or
             secondary endpoint of this study

          -  Lack of compliance

          -  Lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Woong Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DongGuk University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DongGuk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <results_first_submitted>October 15, 2014</results_first_submitted>
  <results_first_submitted_qc>November 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2014</results_first_posted>
  <last_update_submitted>November 16, 2014</last_update_submitted>
  <last_update_submitted_qc>November 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>DongGuk University</investigator_affiliation>
    <investigator_full_name>In Woong Han</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>postcholecystectomy syndrome</keyword>
  <keyword>laparoscopic cholecystectomy</keyword>
  <keyword>Rowachol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Postcholecystectomy Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rowachol</title>
          <description>Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
Rowachol</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rowachol</title>
          <description>Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
Rowachol</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.48" spread="15.56"/>
                    <measurement group_id="B2" value="47.99" spread="13.81"/>
                    <measurement group_id="B3" value="49.78" spread="14.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Number of the Participants Have Postoperative RUQ Pain</title>
        <description>Right upper quadrant(RUQ) pain by European Organization for Research and Treatment of Cancer(EORTC) quality of life questionnaire(QLQ) C-30 No. 9, 19 at baseline and postoperative 3-month.
The pain score of individuals at postoperative 3-month is calculated by EORTC QLQ C-30 manual.
The pain score range is 0 to 100. Higher score means participants feel more pain(worse). If a participant's pain score is over 30, we define he/she has post operative RUQ pain. we use the number of the participants have post operative RUQ pain(score over 30) as the results.</description>
        <time_frame>postoperative 3-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rowachol</title>
            <description>Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
Rowachol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>the Number of the Participants Have Postoperative RUQ Pain</title>
          <description>Right upper quadrant(RUQ) pain by European Organization for Research and Treatment of Cancer(EORTC) quality of life questionnaire(QLQ) C-30 No. 9, 19 at baseline and postoperative 3-month.
The pain score of individuals at postoperative 3-month is calculated by EORTC QLQ C-30 manual.
The pain score range is 0 to 100. Higher score means participants feel more pain(worse). If a participant's pain score is over 30, we define he/she has post operative RUQ pain. we use the number of the participants have post operative RUQ pain(score over 30) as the results.</description>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Results of Postoperative 3-month(Total Bilirubin, Direct Bilirubin)</title>
        <description>laboratory test results(liver function test such as total bilirubin, direct bilirubin) measured at postoperative 3-month of Rowachol group and placebo group.
each result is mean values.</description>
        <time_frame>postoperative 3-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rowachol</title>
            <description>Rowachol treatment with 200mg PO tid, on postoperative 1-day to 3-month
Rowachol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment with 200mg PO tid, on postoperative 1-day to 3-month
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Results of Postoperative 3-month(Total Bilirubin, Direct Bilirubin)</title>
          <description>laboratory test results(liver function test such as total bilirubin, direct bilirubin) measured at postoperative 3-month of Rowachol group and placebo group.
each result is mean values.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.5"/>
                    <measurement group_id="O2" value="0.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.3"/>
                    <measurement group_id="O2" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Results of Postoperative 3-month(Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase)</title>
        <description>laboratory test results(liver function test such as Alkaline phosphatase, Aspartate aminotransferase, Alanine aminotransferase) measured at postoperative 3-month of Rowachol group and placebo group.
each result is mean values.</description>
        <time_frame>postoperative 3-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rowachol</title>
            <description>Rowachol treatment with 200mg PO tid, on postoperative 1-day to 3-month
Rowachol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment with 200mg PO tid, on postoperative 1-day to 3-month
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Results of Postoperative 3-month(Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase)</title>
          <description>laboratory test results(liver function test such as Alkaline phosphatase, Aspartate aminotransferase, Alanine aminotransferase) measured at postoperative 3-month of Rowachol group and placebo group.
each result is mean values.</description>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.8" spread="449.8"/>
                    <measurement group_id="O2" value="209.6" spread="145.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.1" spread="60.5"/>
                    <measurement group_id="O2" value="50.8" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="43.8"/>
                    <measurement group_id="O2" value="56.1" spread="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Results of Postoperative 3-month(WBC Count)</title>
        <description>laboratory test results(WBC count) measured at postoperative 3-month of Rowachol group and placebo group.
each result is mean values.</description>
        <time_frame>postoperative 3-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rowachol</title>
            <description>Rowachol treatment with 200mg PO tid, on postoperative 1-day to 3-month
Rowachol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment with 200mg PO tid, on postoperative 1-day to 3-month
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Results of Postoperative 3-month(WBC Count)</title>
          <description>laboratory test results(WBC count) measured at postoperative 3-month of Rowachol group and placebo group.
each result is mean values.</description>
          <units>cells (10^6/Âµl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.1"/>
                    <measurement group_id="O2" value="7.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>postoperative 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rowachol</title>
          <description>Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
Rowachol</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Post operative minor bile leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. In Woong Han</name_or_title>
      <organization>DongGuk University Ilsan Hospital</organization>
      <email>cardioman76@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

